about
Autoimmune therapies targeting costimulation and emerging trends in multivalent therapeuticsMolecular Insights into γδ T Cell Costimulation by an Anti-JAML AntibodyA new animal model of spontaneous autoimmune peripheral polyneuropathy: implications for Guillain-Barré syndromeT cell immune abnormalities in immune thrombocytopenia.Disease-modifying therapies in multiple sclerosis: an update on recent and ongoing trials and future strategies.Altering immune tolerance therapeutically: the power of negative thinking.Inhibition of cell adhesion and immune responses in the mouse model of collagen-induced arthritis with a peptidomimetic that blocks CD2-CD58 interface interactions.Novel therapies for rheumatoid arthritis.Suppression of established experimental autoimmune uveitis by anti-LFA-1alpha Ab.The net effect of costimulatory blockers is dependent on the subset and activation status of the autoreactive T cells.Abatacept: the first T lymphocyte co-stimulation modulator, for the treatment of rheumatoid arthritis.Potential impact of B cells on T cell function in multiple sclerosisB cells participate in tolerance and autoimmunity through cytokine production.Performance-enhancing drugs: design and production of redirected chimeric antigen receptor (CAR) T cells.Subcutaneous abatacept in rheumatoid arthritis: current update.Analysis of costimulatory molecules OX40/4-1BB (CD134/CD137) detection on chosen mononuclear cells in children and adolescents with Graves' disease during methimazole therapy.Overlooked Mechanisms in Type 1 Diabetes Etiology: How Unique Costimulatory Molecules Contribute to DiabetogenesisPolymorphisms of RPS6KB1 and CD86 associates with susceptibility to multiple sclerosis in Iranian population.Differential effects of Th1, monocyte/macrophage and Th2 cytokine mixtures on early gene expression for immune-related molecules by central nervous system mixed glial cell cultures.Aberrant production of soluble costimulatory molecules CTLA-4, CD28, CD80 and CD86 in patients with systemic lupus erythematosus
P2860
Q26823789-29969651-274D-4494-AB97-40DA69C3EFA9Q27666534-0702A199-F6C4-4C5C-8930-49E658A3A93CQ30565519-BEC098AB-7341-4A0D-AA4D-1E7CDCB894E8Q33417942-FE1FDB1F-2EAC-4E4B-B5F2-E682D1FD513CQ35094706-90481AD0-3C3D-44B2-9925-56C83BF96B45Q35600811-A9E3757D-9D41-4DCF-B9F4-080627A88973Q36338863-58F6E1BE-A01D-4F9F-B738-187AE2DD46DAQ36623081-21E31FEA-F467-4F46-A067-34FBB2C8589CQ36983035-3E1B278E-D3DB-48DD-A3C6-B3B413E93071Q36983052-442D0190-8F52-4EBB-B7B9-3D003BB69D5BQ37032656-F138D1D3-EFA8-4958-A192-66D96DC1BD10Q37957892-366235FF-F3A6-4C7A-B8A6-E56B515F45D5Q38163603-57AF3419-93A5-49BC-BBF1-C5F49A3D3355Q38353123-A95A524A-E574-4F76-ADB9-22CF328E48E1Q38544693-8E0B3ADF-C88F-4CD4-8F64-04C68D2053EBQ39744605-86316677-62C8-43C7-BCF6-71D206A85AC3Q41526144-058D0E89-C803-4FC0-9684-8B3797002B8EQ51197012-BD9928BC-D968-401B-AB13-E3EA134B4CA3Q51586474-F1784FB0-8005-434A-9579-95E2A25F5D65Q56902724-2B17388F-9B51-4890-8619-8CC75A0BC28F
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Targeting T cell costimulation in autoimmune disease.
@ast
Targeting T cell costimulation in autoimmune disease.
@en
Targeting T cell costimulation in autoimmune disease.
@nl
type
label
Targeting T cell costimulation in autoimmune disease.
@ast
Targeting T cell costimulation in autoimmune disease.
@en
Targeting T cell costimulation in autoimmune disease.
@nl
prefLabel
Targeting T cell costimulation in autoimmune disease.
@ast
Targeting T cell costimulation in autoimmune disease.
@en
Targeting T cell costimulation in autoimmune disease.
@nl
P2860
P356
P1476
Targeting T cell costimulation in autoimmune disease.
@en
P2093
Michael K Racke
Rodney W Stuart
P2860
P304
P356
10.1517/14728222.6.3.275
P407
P577
2002-06-01T00:00:00Z